Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter Joe B Putnam, MD, Garrett L Walsh, MD, Stephen G Swisher,

Slides:

Advertisements

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Advertisements

Aortic Valve Replacement With Patch Enlargement of the Aortic Annulus

Photodynamic Laser Therapy for Lesions in the Airway

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution Linda W. Martin, MD, Arlene.

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Management of Malignant Pleural Effusions Using the Pleurx Catheter

Masatsugu Hamaji, MD, Syed Osman Ali, MD, Bryan M. Burt, MD

Primary non-Hodgkin’s lymphoma of the lung

Malignant minor pleural effusion detected on thoracotomy for patients with non–small cell lung cancer: is tumor resection beneficial for prognosis? Noriyoshi.

Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability? Tirone E. David, MD, Susan Armstrong, MS,

Existing General Population Models Inaccurately Predict Lung Cancer Risk in Patients Referred for Surgical Evaluation James M. Isbell, MD, MSCI, Stephen.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Surgical Results and Prognostic Factors in Early Non–Small Cell Lung Cancer José Padilla, MD, Vı́ctor Calvo, MD, Juan C Peñalver, MD, Gabriel Sales, MD,

Mark R. Katlic, MD, Matthew A. Facktor, MD

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population Edmund S. Kassis, MD, Ara A. Vaporciyan,

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Anterior Approaches to the Thoracic Spine in Patients With Cancer: Indications and Results Garrett L Walsh, Ziya L Gokaslan, Ian E McCutcheon, Michael.

A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion Sunil Gandhi, MD, Garrett L Walsh, MD, Ritsuko Komaki, MD, Ziya.

Andrew D. Shaw, MB, Ara A. Vaporciyan, MD, Xifeng Wu, MD, Terri M

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G

Non-Small Cell Lung Cancer Resection in Lymphoma Patients

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

David C. Rice, MB, BCh, Matthew A

Pneumonectomy for stage i (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival Christos Alexiou, FRCS, David Beggs, FETCS,

Combined Resection of Superior Vena Cava for Lung Carcinoma: Prognostic Significance of Patterns of Superior Vena Cava Invasion Kenji Suzuki, MD, Hisao.

Sex-associated differences in survival of patients undergoing resection for lung cancer Mark K Ferguson, MD, Jun Wang, MD, Philip C Hoffman, MD, Daniel.

Anthony J. Ascioti, MD, Wayne L. Hofstetter, MD, Michael J

Gangrene of the Lung: Treatment in Two Stages

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Mark K Ferguson, MD, Amy G Lehman, BA The Annals of Thoracic Surgery

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Prognostic factors in clinical stage I non–small cell lung cancer

Expression of Nuclear Factor-κB and Its Clinical Significance in Nonsmall-Cell Lung Cancer Zhenfa Zhang, MD, Jianqun Ma, MD, Ni Li, PhD, Nan Sun, MD,

Age-Dependent Gender Disparities in Post Lung Transplant Survival Among Patients With Idiopathic Pulmonary Fibrosis Shahid I. Sheikh, MD, Don Hayes,

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.

Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma David C. Rice, MB, BCh, Craig.

Robert R. McMillan, MD, MPH, Camelia S. Sima, MD, MS, Nicole H

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Journal of Thoracic Oncology

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Douglas E. Paull, MD, Glenda M. Updyke, PA-C, Michael A

Management of Primary Pulmonary Artery Sarcomas

David C. Rice, MB, BCh, Jeremy J. Erasmus, MD, Craig W

Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer Stephen G. Swisher, MDa, Linda DeFord, MSb, Kelly.

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD,

Is there a role for pneumonectomy in pulmonary metastases?1

Predictors of Recurrent Pulmonary Metastases and Survival After Pulmonary Metastasectomy for Colorectal Cancer Shanda H. Blackmon, MD, MPH, Elizabeth.

Repair of Thoracoabdominal Aortic Aneurysms in Octogenarians

Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Beware the malignant jellyfish

Prognostic Factors and Surgical Indications of Pulmonary Epithelioid Hemangioendothelioma: A Review of the Literature Patrick Bagan, MD, Mohammed Hassan,

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Neal S Goldstein, MD The Annals of Thoracic Surgery

A Propensity-Matched Comparison of Pleurodesis or Tunneled Pleural Catheter in Patients Undergoing Diagnostic Thoracoscopy for Malignancy Richard K.

Lobectomy for Lung Cancer at Veterans Administration Medical Center Versus Academic Medical Center Travis Geraci, MD, Vanessa Baratta, MD, John Young,

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

Esophagectomy for T1 Esophageal Cancer: Outcomes in 100 Patients and Implications for Endoscopic Therapy Arjun Pennathur, MD, Andrew Farkas, BA, Alyssa.

Visceral Pleural Invasion Is Not a Significant Prognostic Factor in Patients With a Part- Solid Lung Cancer Aritoshi Hattori, MD, Kenji Suzuki, MD, Takeshi.

Improved Long-Term Outcome With Chemoradiotherapy Strategies in Esophageal Cancer Stephen G. Swisher, MD, Wayne Hofstetter, MD, Ritsuko Komaki, MD, Arlene.

Jenifer L. Marks, MD, Wayne Hofstetter, MD, Arlene M

Video-Assisted Thoracoscopic Surgery Is a Safe and Effective Alternative to Thoracotomy for Anatomical Segmentectomy in Patients With Clinical Stage I.

The risk of second primary tumors after resection of stage I nonsmall cell lung cancer David Rice, MB, BCh, Hyung-Woo Kim, MS, Anita Sabichi, MD, Scott.

Presentation transcript:

Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter Joe B Putnam, MD, Garrett L Walsh, MD, Stephen G Swisher, MD, Jack A Roth, MD, Douglas M Suell, MD, Ara A Vaporciyan, MD, W.Roy Smythe, MD, Kelly W Merriman, MS, Linda L DeFord, MS The Annals of Thoracic Surgery Volume 69, Issue 2, Pages 369-375 (February 2000) DOI: 10.1016/S0003-4975(99)01482-4

Fig 1 Overall survival for all patients with malignant pleural effusion (n = 168). Median survival is 3.48 months. The Annals of Thoracic Surgery 2000 69, 369-375DOI: (10.1016/S0003-4975(99)01482-4)

Fig 2 Survival in MPE by histology. Primary histology shown as lung (circles), breast (squares), other (triangles), or lymphoma (vertical lines). Censored patients are shown. Median survival for lung cancer patients (n = 61) was 2.07 ± 0.71 months, for breast cancer (n = 39) was 4.50 ± 1.27 months, for other histology (n = 56) was 4.14 ± 1.73 months, and for lymphoma, median was not reached at 48 months (p = 0.0017 log rank; p = 0.0215 Breslow). The Annals of Thoracic Surgery 2000 69, 369-375DOI: (10.1016/S0003-4975(99)01482-4)

Fig 3 Survival in MPE by treatment group. Treatment groups are shown inpatient CT (circles), as inpatient PC (squares), or outpatient PC (triangles). Censored patients are shown. Median survival for inpatient CT (n = 68) was 2.24 ± 0.72 (95% confidence interval 0.83 to 3.64), for inpatient PC (n = 40) was 2.66 ± 0.89 (95% confidence interval 0.92 to 4.40), and for outpatient PC (n = 60) was 5.85 ± 2.67 (95% confidence interval 0.62 to 11.08) (p = 0.148 log-rank; p = 0.0237 Breslow). The Annals of Thoracic Surgery 2000 69, 369-375DOI: (10.1016/S0003-4975(99)01482-4)